{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:26:51Z","timestamp":1790116011777,"version":"4.0.1"},"reference-count":131,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The prevalence of atrial fibrillation (AF) is increasing and often coexists with frailty. The management of anticoagulation therapy in frail older adults with AF is especially challenging due to the high risk of bleeding complications. The aim of this narrative review is to provide a comprehensive overview of current evidence about the management of anticoagulation in frail older adults with non-valvular AF. First, frailty itself should not be considered a contraindication. A comprehensive geriatric assessment is recommended to identify and potentially address conditions that may increase the risk of bleeding, such as inappropriately prescribed medications or malnutrition. Overall, the net clinical benefit remains in favour of oral anticoagulation in frail older adults, even if it decreases with increasing frailty severity. Direct Oral Anticoagulants (DOACs) show a better effectiveness and safety profile compared with Vitamin K antagonists (VKAs) in this population. Among DOACs, apixaban seems to be the safest. Also, edoxaban at a very low dosage (15 mg\/day) could be an effective therapy in patients for whom the standard anticoagulation is contraindicated. Moreover, switching from VKAs to DOACs in frail older adults is a complex decision and should be personalized according to the stability of the ongoing anticoagulant therapy, the bleeding risk profile, and the severity of frailty. Finally, although further studies are required to confirm their effectiveness, factor XIa inhibitors are emerging as new promising alternative therapies because they have been associated with a lower bleeding risk compared with DOACs.<\/jats:p>","DOI":"10.3390\/jcm14228079","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:46:22Z","timestamp":1763138782000},"page":"8079","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anticoagulation in Frail Older Adults with Non-Valvular Atrial Fibrillation: Clinical Challenges and Personalized Approach"],"prefix":"10.3390","volume":"14","author":[{"given":"Elisa","family":"Fabbri","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"},{"name":"Division of Internal Medicine, Morgagni-Pierantoni Hospital, 47121 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7401-1127","authenticated-orcid":false,"given":"Lorenzo","family":"Maestri","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Morgagni-Pierantoni Hospital, 47121 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Muratori","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Morgagni-Pierantoni Hospital, 47121 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2255838","DOI":"10.1001\/jamanetworkopen.2022.55838","article-title":"Prevalence and Incidence of Atrial Fibrillation Among Older Primary Care Patients","volume":"6","author":"Khurshid","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Testa, C., Salvi, M., Zucchini, I., Cattabiani, C., Giallauria, F., Petraglia, L., Leosco, D., Lauretani, F., and Maggio, M. (2025). Atrial Fibrillation as a Geriatric Syndrome: Why Are Frailty and Disability Often Confused? A Geriatric Perspective from the New Guidelines. Int. J. Environ. Res. Public. Health, 22.","DOI":"10.3390\/ijerph22020179"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra2301292","article-title":"Frailty in Older Adults","volume":"391","author":"Kim","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"105","article-title":"Atrial fibrillation and frailty","volume":"17","author":"Guo","year":"2020","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101652","DOI":"10.1016\/j.arr.2022.101652","article-title":"Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients","volume":"79","author":"Proietti","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104159","DOI":"10.1016\/j.numecd.2025.104159","article-title":"Frailty increases the risk of hospitalization for atrial fibrillation in older adults: A population-based cohort study","volume":"35","author":"Trevisan","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/jgs.18001","article-title":"Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants","volume":"70","author":"Candeloro","year":"2022","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100430","DOI":"10.1016\/j.jnha.2024.100430","article-title":"Poor clinical outcomes associated to multimorbidity, frailty and malnutrition in patients with atrial fibrillation","volume":"29","author":"Lip","year":"2025","journal-title":"J. Nutr. Health Aging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"euae173","DOI":"10.1093\/europace\/euae173","article-title":"Atrial fibrillation accelerates functional decline in older adults: A 15-year follow-up population-based study","volume":"26","author":"Okoye","year":"2024","journal-title":"Europace"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.4022\/jafib.1870","article-title":"What is the Impact of Frailty on Prescription of Anticoagulation in Elderly Patients with Atrial Fibrillation? A Systematic Review and Meta-Analysis","volume":"10","author":"Oqab","year":"2018","journal-title":"J. Atr. Fibrillation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"afac192","DOI":"10.1093\/ageing\/afac192","article-title":"Epidemiology and impact of frailty in patients with atrial fibrillation in Europe","volume":"51","author":"Proietti","year":"2022","journal-title":"Age Ageing"},{"key":"ref_14","first-page":"77","article-title":"The Introduction of Direct Oral Anticoagulants Has Not Resolved Treatment Gaps for Frail Patients with Nonvalvular Atrial Fibrillation","volume":"38","author":"Orlandi","year":"2022","journal-title":"Can. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1055\/s-0042-1756355","article-title":"GLORIA-AF Investigators. Clinical Complexity Domains Anticoagulation Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb. Haemost."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2242964","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in Use of Oral Anticoagulants in Older Adults with Newly Diagnosed Atrial Fibrillation, 2010\u20132020","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"D\u00edez-Villanueva, P., Cos\u00edn-Sales, J., Rold\u00e1n-Schilling, V., Barrios, V., Riba-Art\u00e9s, D., and Gav\u00edn-Sebasti\u00e1n, O. (2023). RE_BELD Spanish Investigator\u2019s Group. Use of Direct Acting Oral Anticoagulants in Elderly Patients with Atrial Fibrillation: A Multicenter, Cross-Sectional Study in Spain. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031224"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102974","DOI":"10.1016\/j.eclinm.2024.102974","article-title":"Adverse events in clinically complex elderly patients with atrial fibrillation according to oral anticoagulation status","volume":"78","author":"Bucci","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.hrthm.2024.11.017","article-title":"Accelerated biological aging and risk of atrial fibrillation: A cohort study","volume":"22","author":"Yang","year":"2025","journal-title":"Heart Rhythm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: Evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits","volume":"62","author":"Rockwood","year":"2007","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1532-5415.2006.00738.x","article-title":"Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70","volume":"54","author":"Rockwood","year":"2006","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5770\/cgj.23.463","article-title":"Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources","volume":"23","author":"Rockwood","year":"2020","journal-title":"Can. Geriatr. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e076246","DOI":"10.1136\/bmj-2023-076246","article-title":"Management of atrial fibrillation in older adults","volume":"386","author":"Parks","year":"2024","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/ggi.70046","article-title":"Frailty, multimorbidity, and polypharmacy: Proposal of the new concept of the geriatric triangle","volume":"25","author":"Umegaki","year":"2025","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e005657","DOI":"10.1161\/JAHA.117.005657","article-title":"Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients with Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation)","volume":"6","author":"Patti","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bonanad, C., Formiga, F., Anguita, M., Petidier, R., and Gull\u00f3n, A. (2022). Oral Anticoagulant Use and Appropriateness in Elderly Patients with Atrial Fibrillation in Complex Clinical Conditions: ACONVENIENCE Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11247423"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ahj.2023.03.015","article-title":"Association of CHA2DS2-VASc and HAS-BLED to frailty and frail outcomes: From the TREAT-AF study","volume":"261","author":"Pundi","year":"2023","journal-title":"Am. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e062353","DOI":"10.1136\/bmjopen-2022-062353","article-title":"Treatment patterns for oral anticoagulants in older patients with atrial fibrillation: A retrospective, cross-sectional, nationwide study from Denmark","volume":"12","author":"Rasmussen","year":"2022","journal-title":"BMJ Open"},{"key":"ref_35","first-page":"46","article-title":"Assessing the Appropriateness of Oral Anticoagulation for Atrial Fibrillation in Advanced Frailty: Use of Stroke and Bleeding Risk-Prediction Models","volume":"6","author":"Igras","year":"2017","journal-title":"J. Frailty Aging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e006212","DOI":"10.1161\/CIRCOUTCOMES.119.006212","article-title":"Net Clinical Benefit of Oral Anticoagulation Among Older Adults with Atrial Fibrillation","volume":"12","author":"Shah","year":"2019","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/STROKEAHA.121.036757","article-title":"Effectiveness and Safety of Anticoagulation Therapy in Frail Patients with Atrial Fibrillation","volume":"53","author":"Kim","year":"2022","journal-title":"Stroke"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/STROKEAHA.123.044407","article-title":"Net Clinical Benefit of Oral Anticoagulation Among Frail Patients with Atrial Fibrillation: Nationwide Cohort Study","volume":"55","author":"Jensen","year":"2024","journal-title":"Stroke"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jamda.2024.01.011","article-title":"Predictors and Outcomes of Oral Anticoagulant Deprescribing in Geriatric Inpatients with Atrial Fibrillation: A Retrospective Multicenter Cohort Study","volume":"25","author":"Brunetti","year":"2024","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Proietti, M., Camera, M., Gallieni, M., Gianturco, L., Gidaro, A., Piemontese, C., Pizzetti, G., Redaelli, F., Scimeca, B., and Tadeo, C.S. (2022). Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document. J. Pers. Med., 12.","DOI":"10.3390\/jpm12030469"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100386","DOI":"10.1016\/j.lanepe.2022.100386","article-title":"Temporal trends and patterns in atrial fibrillation incidence: A population-based study of 3\u00b74 million individuals","volume":"17","author":"Wu","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.mayocp.2019.06.012","article-title":"Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use","volume":"94","author":"Proietti","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"111482","DOI":"10.1016\/j.exger.2021.111482","article-title":"Relationship between multimorbidity and outcomes in atrial fibrillation","volume":"153","author":"Proietti","year":"2021","journal-title":"Exp. Gerontol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ehjqcco\/qcaa070","article-title":"Treatment of older patients with atrial fibrillation by morbidity burden","volume":"8","author":"Rasmussen","year":"2022","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_45","first-page":"1","article-title":"Atrial fibrillation in older adults with cancer","volume":"19","author":"Kumar","year":"2022","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e13745","DOI":"10.1111\/eci.13745","article-title":"ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry","volume":"52","author":"Ding","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jth.12874","article-title":"Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: Insights from the RE-LY trial","volume":"13","author":"Westenbrink","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/s-0043-1770724","article-title":"Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis","volume":"125","author":"Zheng","year":"2025","journal-title":"Thromb. Haemost."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Amrouch, C., Vetrano, D.L., Damiano, C., Dai, L., Calder\u00f3n-Larra\u00f1aga, A., Grymonprez, M., Proietti, M., Lip, G.Y.H., Johnsen, S.P., and Wastesson, J.W. (2024). Potentially inappropriate prescribing in polymedicated older adults with atrial fibrillation and multimorbidity: A Swedish national register-based cohort study. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1476464"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCULATIONAHA.121.055018","article-title":"Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration","volume":"145","author":"Rivard","year":"2022","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhang, C., Gu, Z.C., Shen, L., Pan, M.M., Yan, Y.D., Pu, J., Liu, X.Y., and Lin, H.W. (2018). Non-vitamin K Antagonist Oral Anticoagulants and Cognitive Impairment in Atrial Fibrillation: Insights From the Meta-Analysis of Over 90,000 Patients of Randomized Controlled Trials and Real-World Studies. Front. Aging Neurosci., 10.","DOI":"10.3389\/fnagi.2018.00258"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1161\/STROKEAHA.120.033338","article-title":"Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients with Atrial Fibrillation","volume":"52","author":"Lee","year":"2021","journal-title":"Stroke"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Agarwal, A., Mostafa, M.A., Ahmad, M.I., and Soliman, E.Z. (2024). Exploring the Link between Anticoagulation, Cognitive Impairment and Dementia in Atrial Fibrillation: A Systematic Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13082418"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.thromres.2024.04.032","article-title":"Oral anticoagulants and cognitive impairment in patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis","volume":"238","author":"Lee","year":"2024","journal-title":"Thromb. Res."},{"key":"ref_55","unstructured":"(2025, November 09). Presented by Dr. Lena Rivard at the American Heart Association Scientific Sessions, Chicago, IL, USA, 16 November 2024. Available online: https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2024\/11\/15\/15\/17\/brain-af."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Rocheeld, J., Kusayev, J., Frishman, W.H., and Aronow, W.S. (2025). Anticoagulation in Atrial Fibrillation and Dementia. Cardiol Rev.","DOI":"10.1097\/CRD.0000000000001011"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105601","DOI":"10.1016\/j.archger.2024.105601","article-title":"Impact of depression and cardiovascular risk factors on cognitive impairment in patients with atrial fibrillation: A Systematic review and meta-analysis","volume":"128","author":"Pino","year":"2025","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e031281","DOI":"10.1161\/JAHA.123.031281","article-title":"Association of Depression and Adherence to Oral Anticoagulation in Patients with Atrial Fibrillation","volume":"12","author":"Lapa","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e039885","DOI":"10.1161\/JAHA.124.039885","article-title":"Association of Social Disconnection with the Incidence and Prognosis of Atrial Fibrillation: A Multistate Analysis","volume":"14","author":"Qiao","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"105764","DOI":"10.1016\/j.jamda.2025.105764","article-title":"The Impact of Atrial Fibrillation on Physical Performance in Older Adults: A Longitudinal Study in Relation to Cognitive Function","volume":"26","author":"Ceolin","year":"2025","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Romiti, G.F., Corica, B., Bucci, T., Boriani, G., Olshansky, B., Chao, T.F., Huisman, M.V., Proietti, M., and Lip, G.Y.H. (2025). GLORIA-AF Investigators. History of falls in patients with atrial fibrillation and risk of major outcomes: Analysis from the Prospective GLORIA-AF Registry. Geroscience.","DOI":"10.1007\/s11357-025-01852-x"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Huang, M., Zhang, S., Xu, C., Li, B., Lai, Y., Zhan, R., Guo, Y., Ma, Y., Liao, X., and Wu, X. (2025). Malnutrition increases the risk of atrial fibrillation. BMC Cardiovasc. Disord., 25.","DOI":"10.1186\/s12872-025-05107-7"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e13130","DOI":"10.1111\/anec.13130","article-title":"Effect of nutritional status on adverse clinical events in elderly patients with nonvalvular atrial fibrillation: A retrospective cohort study","volume":"29","author":"Zhang","year":"2024","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: An integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjmed.2018.06.012","article-title":"Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway","volume":"131","author":"Proietti","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"afac245","DOI":"10.1093\/ageing\/afac245","article-title":"mAF-App II Trial Investigators. Mobile health technology integrated care in older atrial fibrillation patients: A subgroup analysis of the mAFA-II randomised clinical trial","volume":"51","author":"Guo","year":"2022","journal-title":"Age Ageing"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/eurheartj\/ehac265","article-title":"A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: The AFFIRMO Consortium","volume":"43","author":"Johnsen","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/eurheartj\/ehab672","article-title":"ESC and EHRA lead a path towards integrated care for multimorbid atrial fibrillation patients: The Horizon 2020 EHRA-PATHS project","volume":"43","author":"Heidbuchel","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2024.04.009","article-title":"Oral anticoagulant therapy in older adults","volume":"238","author":"Stuby","year":"2024","journal-title":"Thromb. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40266-024-01138-5","article-title":"Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Decade of Experience","volume":"41","author":"Spruit","year":"2024","journal-title":"Drugs Aging"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and Safety of Edoxaban in Elderly Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial","volume":"5","author":"Kato","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jjcc.2018.01.015","article-title":"Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis","volume":"72","author":"Kim","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.archger.2018.12.013","article-title":"Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis","volume":"81","author":"Caldeira","year":"2019","journal-title":"Arch Gerontol. Geriatr."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","article-title":"Meta-Analysis of Direct-Acting Oral Anticoagulants Compared with Warfarin in Patients >75 Years of Age","volume":"123","author":"Malik","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Deng, K., Cheng, J., Rao, S., Xu, H., Li, L., and Gao, Y. (2020). Efficacy and Safety of Direct Oral Anticoagulants in Elderly Patients with Atrial Fibrillation: A Network Meta-Analysis. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00107"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bonanad, C., Garc\u00eda-Blas, S., Torres Llergo, J., Fern\u00e1ndez-Olmo, R., D\u00edez-Villanueva, P., Ariza-Sol\u00e9, A., Mart\u00ednez-Sell\u00e9s, M., Raposeiras, S., Ayesta, A., and Bertomeu-Gonz\u00e1lez, V. (2021). Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10225268"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"afac292","DOI":"10.1093\/ageing\/afac292","article-title":"Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: A systematic review with traditional and network meta-analysis","volume":"51","author":"Lee","year":"2022","journal-title":"Age Ageing"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e030380","DOI":"10.1161\/JAHA.123.030380","article-title":"Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients with Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials","volume":"12","author":"Lin","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s11357-023-00825-2","article-title":"Safety outcomes of direct oral anticoagulants in older adults with atrial fibrillation: A systematic review and meta-analysis of (subgroup analyses from) randomized controlled trials","volume":"46","author":"Doni","year":"2024","journal-title":"Geroscience"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/jgs.15956","article-title":"Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients","volume":"67","author":"Deitelzweig","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: A multinational population-based cohort study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/ehjqcco\/qcab025","article-title":"Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: Results from the All Nippon AF In the Elderly (ANAFIE) Registry","volume":"8","author":"Yamashita","year":"2022","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"102687","DOI":"10.1016\/j.jaccas.2024.102687","article-title":"Anticoagulation in Atrial Fibrillation Patients with Frailty","volume":"29","author":"Lee","year":"2024","journal-title":"JACC Case Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/STROKEAHA.123.045098","article-title":"Effectiveness and Safety of Edoxaban Compared with Apixaban in Elderly Patients with Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study","volume":"55","author":"Chiv","year":"2024","journal-title":"Stroke"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel (2023). American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc., 71, 2052\u20132081.","DOI":"10.1111\/jgs.18372"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Alshehri, A.M., Alfehaid, L., Alhawas, S., Alsuwaylihi, A., Alarifi, A., and Al Yami, M.S. (2025). Comparison of Safety and Effectiveness Between Direct Oral Anticoagulants and Vitamin K Antagonists in Dementia Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14165758"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2018.09.017","article-title":"Outcomes of apixaban versus warfarin in patients with atrial fibrillation multi-morbidity: Insights from the ARISTOTLE trial","volume":"208","author":"Alexander","year":"2019","journal-title":"Am. Heart J."},{"key":"ref_96","first-page":"i2868","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Brouwer","year":"2016","journal-title":"BMJ"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","article-title":"Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis","volume":"68","author":"Steffel","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Wilkinson, C., Wu, J., Searle, S.D., Todd, O., Hall, M., Kunadian, V., Clegg, A., Rockwood, K., and Gale, C.P. (2020). Clinical outcomes in patients with atrial fibrillation and frailty: Insights from the ENGAGE AF-TIMI 48 trial. BMC Med., 18.","DOI":"10.1186\/s12916-020-01870-w"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e008643","DOI":"10.1161\/JAHA.118.008643","article-title":"Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients with Nonvalvular Atrial Fibrillation","volume":"7","author":"Martinez","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7326\/M20-7141","article-title":"Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults with Atrial Fibrillation: A Cohort Study","volume":"174","author":"Kim","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/joim.13140","article-title":"Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: Insights from the ARISTOPHANES study","volume":"289","author":"Lip","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e2342264","DOI":"10.1001\/jamanetworkopen.2023.42264","article-title":"Frailty, Home Time, and Health Care Costs in Older Adults with Atrial Fibrillation Receiving Oral Anticoagulants","volume":"6","author":"Lin","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ehjcvp\/pvad091","article-title":"Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation","volume":"10","author":"Ording","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"907197","DOI":"10.3389\/fcvm.2022.907197","article-title":"Effectiveness and Safety of DOACs vs. Warfarin in Patients with Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis","volume":"9","author":"Zeng","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.5527\/wjn.v14.i2.105803","article-title":"Chronic kidney disease in geriatric patients: Estimating glomerular filtration rate in older patients with comorbidities","volume":"14","author":"Gembillo","year":"2025","journal-title":"World J. Nephrol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40266-022-00999-y","article-title":"Frailty as a Marker for the Plasma Concentrations of Direct Oral Anticoagulants in Older Patients: Results of an Exploratory Study","volume":"40","author":"Eidam","year":"2023","journal-title":"Drugs Aging"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jgs.16992","article-title":"Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults with Atrial Fibrillation","volume":"69","author":"Bendayan","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e014108","DOI":"10.1161\/JAHA.119.014108","article-title":"Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations with Geriatric Conditions Among Older Patients with Atrial Fibrillation: The SAGE-AF Study","volume":"9","author":"Sanghai","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40266-023-01081-x","article-title":"Prevalence and factors associated with inappropriate dosing of apixaban and rivaroxaban in hospitalized older adults with atrial fibrillation: A cross-sectional study","volume":"41","author":"Decaix","year":"2024","journal-title":"Drugs Aging"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/bcp.16010","article-title":"Appropriateness of direct oral anticoagulant prescribing in older subjects with atrial fibrillation discharged from acute medical wards","volume":"90","author":"Soraci","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"euad302","DOI":"10.1093\/europace\/euad302","article-title":"Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: Results from the French National Prospective Registry: PAFF","volume":"25","author":"Guenoun","year":"2023","journal-title":"Europace"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1253\/circj.CJ-23-0143","article-title":"Relationship Between Direct Oral Anticoagulant Doses and Clinical Outcomes in Elderly Patients with Non-Valvular Atrial Fibrillation\u2014ANAFIE Registry Sub-Analysis","volume":"87","author":"Akao","year":"2023","journal-title":"Circ. J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2022.04.062","article-title":"Clinical effects of off-label reduced doses of Direct Oral Anticoagulants: A systematic review and meta-analysis","volume":"362","author":"Pereira","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.thromres.2022.11.003","article-title":"Safety and efficacy of direct oral anticoagulants in geriatric patients with non-valvular atrial fibrillation: A single-center retrospective study","volume":"221","author":"Sabbatinelli","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.amjmed.2020.12.022","article-title":"Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter","volume":"134","author":"Ashraf","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamacardio.2016.1829","article-title":"Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients with Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial","volume":"1","author":"Alexander","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e2228500","DOI":"10.1001\/jamanetworkopen.2022.28500","article-title":"Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients with Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial","volume":"5","author":"Akashi","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e031506","DOI":"10.1161\/JAHA.123.031506","article-title":"Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients with Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial","volume":"13","author":"Akao","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/CIRCULATIONAHA.121.057190","article-title":"Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients with Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial","volume":"145","author":"Yoshida","year":"2022","journal-title":"Circulation"},{"key":"ref_122","first-page":"279","article-title":"Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.7326\/M21-1474","article-title":"Rivaroxaban Is Associated with Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score-Weighted Study","volume":"174","author":"Ingason","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jacc.2025.05.060","article-title":"Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy","volume":"86","author":"Nicolau","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): A multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus Apixaban in Patients with Atrial Fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"10760296251335967","DOI":"10.1177\/10760296251335967","article-title":"A Systematic Review of Factor XI\/XIa Inhibitors Versus Direct Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"31","author":"Xue","year":"2025","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjcard.2023.03.015","article-title":"Impact of Frailty on In-Hospital Outcomes in Patients Who Underwent Percutaneous Left Atrial Appendage Occlusion","volume":"196","author":"Agarwal","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10840-023-01662-1","article-title":"Frailty and associated outcomes in patients undergoing percutaneous left atrial appendage occlusion: Findings from the NCDR LAAO registry","volume":"67","author":"Darden","year":"2024","journal-title":"J. Interv. Card. Electrophysiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8079\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:05:13Z","timestamp":1763139913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":131,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14228079"],"URL":"https:\/\/doi.org\/10.3390\/jcm14228079","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}